Search results
Results from the WOW.Com Content Network
[4] [8] [9] It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month. [4] [5] It is also approved for use in Canada. [1] In the European Union, the two medications are approved separately and have different brand names: Vocabria (for cabotegravir) and Rekambys (for rilpivirine). [10 ...
Cabotegravir was approved for medical use in the European Union in December 2020. [10] In December 2021, the U.S. Food and Drug Administration (FDA) approved cabotegravir for pre-exposure prophylaxis. [16] The FDA granted the approval of Apretude to Viiv. [16] Zimbabwe became the first African country to approve the drug in October 2022. [26]
Rilpivirine, sold under the brand name Edurant among others, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [6] [7] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...
FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA), 2004 Foscarnet: Herpes: Pyrophosphate analogue DNA polymerase inhibitor: 1991 Ganciclovir (Cytovene) [9] Cytomegalovirus (CMV) [10] Competitive nucleoside analogue dGTP inhibitor 1988 Ibacitabine: Herpes labialis ...
‘Long-awaited’ drug to treat food allergies, including nuts, gets FDA approval — could ‘redefine’ treatment Brooke Steinberg February 19, 2024 at 1:19 PM
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.